sirolimus and Cholangitis--Sclerosing

Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease characterized by fibro-obliterative inflammation of the hepatic bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and in some cases, cholangiocarcinoma. Despite clinical trials of nearly 20 different pharmacotherapies over several decades, safe and effective medical therapy, albeit critically needed, remains to be established. PSC is pathogenically complex, with genetic, immune, enteric microbial, environmental and other factors being potentially involved and, thus, not surprisingly, it manifests as a clinically heterogeneous disease with a relatively unpredictable course. It is likely that this complexity and clinical heterogeneity are responsible for the negative results of clinical trials, but novel insights about and approaches to PSC may shift this trend. The authors herein provide a review of previously tested pharmacologic agents, discuss emerging fundamental concepts and present viewpoints regarding how identifying therapies for PSC may evolve over the next several years.

Topics: Animals; Anti-Bacterial Agents; Cholangitis, Sclerosing; Disease Models, Animal; Endoscopy, Digestive System; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Receptors, Lymphocyte Homing; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome

Topics: Cholangitis, Sclerosing; Humans; Immunosuppressive Agents; Sirolimus